Acquiring Company
AbbVie Inc.
Acquired Company
Gilgamesh Pharmaceuticals
North ChicagoNew YorkManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaHealthcareDescription
AbbVie has acquired Gilgamesh Pharmaceuticals' bretisilocin, a Phase 2 psychedelic treatment for major depressive disorder. This acquisition highlights AbbVie's commitment to expanding its innovative therapies in mental health. Additionally, AbbVie has fortified its immunology portfolio through the acquisition of Capstan Therapeutics. These strategic moves are aimed at broadening therapeutic options and enhancing revenue streams.
Quick answer
AbbVie Inc. is acquiring Gilgamesh Pharmaceuticals, announced September 3, 2025. AbbVie Inc. is based in North Chicago, Illinois, United States.
- How much did AbbVie Inc. pay for Gilgamesh Pharmaceuticals?
- The deal value was not disclosed.
- What does AbbVie Inc. do?
- Venture capital subsidiary of Abbvie
- Where are AbbVie Inc. and Gilgamesh Pharmaceuticals based?
- AbbVie Inc. is based in North Chicago, Illinois, United States. Gilgamesh Pharmaceuticals is based in New York, New York, United States.
- Who are the decision-makers at AbbVie Inc?
- Fundz holds 2 contacts at AbbVie Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie completes acquisition of Capstan Therapeutics (August 19, 2025)
- AbbVie acquires Bretisilocin for mental health expansion (October 15, 2025)
- Supernus acquires SAGE Therapeutics for USD 8.50/share (July 31, 2025)
- AbbVie to acquire Gilgamesh Pharmaceuticals (July 31, 2025)
- Pfizer acquires Metsera for $7.3 billion, $7.3B (October 13, 2025)
- Pfizer to acquire Metsera for $7.3 billion, $7.3B (September 22, 2025)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Gilgamesh Pharmaceuticals?
Gilgamesh Pharmaceuticals was acquired by AbbVie Inc., based in North Chicago. The deal was reported on September 3, 2025. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Gilgamesh Pharmaceuticals?
AbbVie Inc.'s acquisition of Gilgamesh Pharmaceuticals was reported on September 3, 2025. AbbVie has acquired Gilgamesh Pharmaceuticals' bretisilocin, a Phase 2 psychedelic treatment for major depressive disorder. This acquisition highlights AbbVie's commitment to expanding its innovative therapies in mental health. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Gilgamesh Pharmaceuticals do?
Gilgamesh is a pioneering, mental health science-focused biotechnology company. It is privately held, operating in Healthcare, and is based in New York.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.